Pace Life Sciences Expands Sterile Filling Capabilities
Pace Life Sciences, a US-based contract research, development, and manufacturing organization (CRDMO), is remodeling and expanding its Salem, NH site to establish the Center of Excellence for Aseptic Fill-Finish Processing.
“Through our continuous improvement initiatives at Pace Life Sciences, our team recognized an opportunity to enhance and expand our capabilities in response to our past success in partnering with clients on small molecule fill finish programs and the increasing demand for fill finish manufacturing generated by growth in biologics and other large molecule products,” stated Dawn Von Rohr, President of Pace Life Sciences. “The remodel of our state-of-the-art facility in Salem, NH, ensures that we can scale alongside our clients as their programs evolve and regulatory expectations advance. We look forward to welcoming visitors to showcase our advanced capabilities and enhancements.”
The expansion of the Salem, NH facility includes the addition of an isolated vial filling line, designed to facilitate smaller batch sizes with high sterility assurance and EU Annex 1 compliance. This fill line, along with other facility enhancements, allows Pace to serve clients requiring cGMP manufacturing in the injectable space for vaccines, gene therapies, antibodies, and protein-based therapeutics.
Registration information for the free open house on July 16th can be found here.
Pace is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.
